Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05708859 · ClinicalTrials.gov registry record · Phase 4
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
A Phase 4 study of Atherosclerosis and Type II Diabetes, sponsored by Matthew J. Budoff.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05708859: Recruiting Phase 4 study of Atherosclerosis and Type II Diabetes, sponsored by Matthew J. Budoff.
NCT05708859 is a Phase 4 study of Atherosclerosis and Type II Diabetes that is actively recruiting participants, run by Matthew J. Budoff. The registered enrollment target is 120 participants, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05708859, a Phase 4 study of Atherosclerosis and Type II Diabetes, is actively recruiting participants, sponsored by Matthew J. Budoff.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
Primary Outcome
Reduction of total non-calcified coronary plaque volume from baseline (start of the study) till the final visit will be measured using Coronary Computed Tomography Angiography (CCTA).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (1)
California
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2026-05 |
| Phase | Phase 4 |
What NCT05708859 shows while recruiting
NCT05708859 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05708859 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05708859 about?
NCT05708859 is a clinical study titled "Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT". A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosc...
What is the current status of trial NCT05708859?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-01-02. Estimated completion is 2026-05.
What conditions does trial NCT05708859 study?
This clinical trial studies the following conditions: Atherosclerosis, Type II Diabetes.
What interventions are being tested in trial NCT05708859?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT05708859?
This trial is sponsored by Matthew J. Budoff, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05708859 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05708859's enrollment target sits among peer trials
120 47th of 69 higher than 22 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RECRUITING · Phase 4
-
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI